STOCK TITAN

[144] FENNEC PHARMACEUTICALS INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Fennec Pharmaceuticals (FENC) filed a Form 144 notifying a proposed sale of 1,775 common shares with an aggregate market value of $16,401.00. The shares are scheduled for sale approximately on 10/10/2025 on NASDAQ. The filing shows the shares were acquired the same day, 10/10/2025, by stock option exercise from the issuer and paid in cash. There were 27,831,698 shares outstanding noted for the class. No securities were reported sold in the prior three months. The filer affirms they are not aware of undisclosed material adverse information and the notice contains the standard attestation language regarding trading plans and criminal penalties for false statements.

Fennec Pharmaceuticals (FENC) ha presentato un Modulo 144 che informa una vendita proposta di 1.775 azioni ordinarie con un valore di mercato complessivo di $16.401,00. Le azioni sono previste per essere vendute circa il 10/10/2025 su NASDAQ. L’atto di deposito mostra che le azioni sono state acquisite lo stesso giorno, 10/10/2025, mediante esercizio di opzioni su azioni da parte dell’emittente e pagate in contanti. Vi erano 27.831.698 azioni in circolazione indicate per la classe. Non sono stati riportati titoli venduti nei tre mesi precedenti. Il dichiarante afferma di non essere a conoscenza di informazioni avverse materialmente non divulgate e l’avviso contiene il linguaggio tipico di attestazione riguardo ai piani di negoziazione e alle pene penali per dichiarazioni false.

Fennec Pharmaceuticals (FENC) presentó un Formulario 144 informando una venta propuesta de 1,775 acciones comunes con un valor de mercado agregado de $16,401.00. Las acciones están programadas para venderse aproximadamente el 10/10/2025 en NASDAQ. El formulario indica que las acciones fueron adquiridas el mismo día, 10/10/2025, mediante ejercicio de opciones sobre acciones por parte del emisor y pagadas en efectivo. Había 27,831,698 acciones en circulación señaladas para la clase. No se reportaron valores vendidos en los tres meses anteriores. El presentante afirma no estar al tanto de información adversa material no divulgada y el aviso contiene el lenguaje de attestación estándar respecto a planes de negociación y sanciones penales por declaraciones falsas.

Fennec Pharmaceuticals (FENC)Form 144를 제출하여 1,775 주의 보통주를 제안된 매매로 통지하였고, 총 시장 가치는 $16,401.00입니다. 주식은 대략 2025-10-10에 NASDAQ에서 매매될 예정입니다. 제출 서류에 따르면 주식은 발행자가 주식매수선택권을 행사하여 같은 날인 2025-10-10에 취득되었고 현금으로 지불되었습니다. 이 클래스의 유통주식 수는 27,831,698주로 기재되어 있습니다. 지난 3개월 동안 매도된 증권은 보고되지 않았습니다. 제출자는 공개되지 않은 중요한 악재 정보에 대해 알고 있지 않다고 확인하며, 알림에는 거래 계획 및 허위 진술에 대한 형사처벌에 관한 표준 확인 문구가 포함되어 있습니다.

Fennec Pharmaceuticals (FENC) a déposé un Formulaire 144 informant d'une vente proposée de 1 775 actions ordinaires d'une valeur marchande globale de $16.401,00. Les actions sont prévues pour être vendues environ le 10/10/2025 sur NASDAQ. Le dossier indique que les actions ont été acquises le même jour, 10/10/2025, par l'exercice d'options sur actions de l'émetteur et payées en espèces. Il y avait 27 831 698 actions en circulation indiquées pour la catégorie. Aucune valeur mobilière n'a été vendue au cours des trois mois précédents. Le déposant affirme ne pas être au courant d'informations défavorables matérielles non divulguées et l'avis contient le langage d'attestation standard concernant les plans de négociation et les sanctions pénales pour les déclarations mensongères.

Fennec Pharmaceuticals (FENC) hat ein Form 144 eingereicht, das einen vorgeschlagenen Verkauf von 1.775 Stammaktien mit einem gesamten Marktwert von 16.401,00 $ ankündigt. Die Aktien sollen voraussichtlich am 10.10.2025 an der NASDAQ verkauft werden. Die Einreichung zeigt, dass die Aktien am selben Tag, dem 10.10.2025, durch Ausübung von Aktienoptionen seitens des Emittenten erworben und in bar bezahlt wurden. Es gab 27.831.698 ausstehende Aktien, die für die Klasse vermerkt sind. In den letzten drei Monaten wurden keine Wertpapiere verkauft. Der Einreicher bestätigt, dass er sich keiner nicht offengelegten materialadversen Informationen bewusst ist, und der Hinweis enthält die standardmäßige Bestätigung über Handelspläne und strafrechtliche Folgen bei falschen Aussagen.

Fennec Pharmaceuticals (FENC) قدمت نموذج 144 للإخطار ببيع مقترح لـ 1,775 سهماً عادياً بإجمالي قيمة سوقية قدرها $16,401.00. من المقرر بيع الأسهم تقريباً في 10/10/2025 في ناسداك. يُظهر الملف أن الأسهم قد اشترِت في اليوم نفسه، 10/10/2025، من خلال تنفيذ خيار شراء أسهم من المصدر ودفع نقداً. كان هناك 27,831,698 سهماً قائماً مذكوراً لهذه الفئة. لم يتم الإبلاغ عن بيع أي أوراق مالية في الأشهر الثلاثة الماضية. يقر المقدم بأنه لا يعلم بوجود معلومات سلبية مادية غير مُبلَّغ عنها ويحتوي الإشعار على لغة الإقرار القياسية المتعلقة بخطط التداول وبالحِقوق الجنائية على التصريحات الكاذبة.

Fennec Pharmaceuticals (FENC) 已提交表格144,通知拟议出售1,775股普通股,合计市值为$16,401.00美元。预计将于2025-10-10NASDAQ出售这些股票。文件显示,该等股票在同一天,即2025-10-10,通过发行方行使股票期权取得并以现金支付。该类别的在外流通股数量为27,831,698股。过去三个月未报告有证券被出售。申报人确认其未获知任何未披露的重要不利信息,通知中包含关于交易计划和对虚假陈述的刑事处罚的标准声明语言。

Positive
  • Full disclosure of proposed sale details including broker, share count, value, and planned sale date
  • Acquisition method transparently stated as a stock option exercise with cash payment on 10/10/2025
  • No prior sales reported in the past three months for the selling person
Negative
  • None.

Insights

Small post‑exercise sale planned by an insider via market broker.

The notice records a proposed open‑market sale of $16,401.00 for 1,775 shares to be executed through Morgan Stanley Smith Barney LLC on 10/10/2025. The shares were acquired by a stock option exercise and paid in cash on the same date, which indicates an immediate post‑exercise disposition rather than a long‑term transfer.

This transaction size represents a small fraction of the class base (27,831,698 outstanding), so it is unlikely to be price‑moving alone. Monitor trade execution on the listed exchange around 10/10/2025 for any clustering with other insider sales that could be material.

Filing follows Rule 144 disclosure and includes standard attestation.

The form includes the required representation that the seller is unaware of any undisclosed material adverse information and notes the possibility of a Rule 10b5‑1 trading plan if applicable. It names the executing broker and furnishes acquisition details (exercise from the issuer, cash payment).

From a compliance perspective, the clear dating of acquisition and planned sale simplifies rule‑144 eligibility review. If a trading plan or instruction date exists, it should be noted to confirm affirmative safe‑harbor timing.

Fennec Pharmaceuticals (FENC) ha presentato un Modulo 144 che informa una vendita proposta di 1.775 azioni ordinarie con un valore di mercato complessivo di $16.401,00. Le azioni sono previste per essere vendute circa il 10/10/2025 su NASDAQ. L’atto di deposito mostra che le azioni sono state acquisite lo stesso giorno, 10/10/2025, mediante esercizio di opzioni su azioni da parte dell’emittente e pagate in contanti. Vi erano 27.831.698 azioni in circolazione indicate per la classe. Non sono stati riportati titoli venduti nei tre mesi precedenti. Il dichiarante afferma di non essere a conoscenza di informazioni avverse materialmente non divulgate e l’avviso contiene il linguaggio tipico di attestazione riguardo ai piani di negoziazione e alle pene penali per dichiarazioni false.

Fennec Pharmaceuticals (FENC) presentó un Formulario 144 informando una venta propuesta de 1,775 acciones comunes con un valor de mercado agregado de $16,401.00. Las acciones están programadas para venderse aproximadamente el 10/10/2025 en NASDAQ. El formulario indica que las acciones fueron adquiridas el mismo día, 10/10/2025, mediante ejercicio de opciones sobre acciones por parte del emisor y pagadas en efectivo. Había 27,831,698 acciones en circulación señaladas para la clase. No se reportaron valores vendidos en los tres meses anteriores. El presentante afirma no estar al tanto de información adversa material no divulgada y el aviso contiene el lenguaje de attestación estándar respecto a planes de negociación y sanciones penales por declaraciones falsas.

Fennec Pharmaceuticals (FENC)Form 144를 제출하여 1,775 주의 보통주를 제안된 매매로 통지하였고, 총 시장 가치는 $16,401.00입니다. 주식은 대략 2025-10-10에 NASDAQ에서 매매될 예정입니다. 제출 서류에 따르면 주식은 발행자가 주식매수선택권을 행사하여 같은 날인 2025-10-10에 취득되었고 현금으로 지불되었습니다. 이 클래스의 유통주식 수는 27,831,698주로 기재되어 있습니다. 지난 3개월 동안 매도된 증권은 보고되지 않았습니다. 제출자는 공개되지 않은 중요한 악재 정보에 대해 알고 있지 않다고 확인하며, 알림에는 거래 계획 및 허위 진술에 대한 형사처벌에 관한 표준 확인 문구가 포함되어 있습니다.

Fennec Pharmaceuticals (FENC) a déposé un Formulaire 144 informant d'une vente proposée de 1 775 actions ordinaires d'une valeur marchande globale de $16.401,00. Les actions sont prévues pour être vendues environ le 10/10/2025 sur NASDAQ. Le dossier indique que les actions ont été acquises le même jour, 10/10/2025, par l'exercice d'options sur actions de l'émetteur et payées en espèces. Il y avait 27 831 698 actions en circulation indiquées pour la catégorie. Aucune valeur mobilière n'a été vendue au cours des trois mois précédents. Le déposant affirme ne pas être au courant d'informations défavorables matérielles non divulguées et l'avis contient le langage d'attestation standard concernant les plans de négociation et les sanctions pénales pour les déclarations mensongères.

Fennec Pharmaceuticals (FENC) hat ein Form 144 eingereicht, das einen vorgeschlagenen Verkauf von 1.775 Stammaktien mit einem gesamten Marktwert von 16.401,00 $ ankündigt. Die Aktien sollen voraussichtlich am 10.10.2025 an der NASDAQ verkauft werden. Die Einreichung zeigt, dass die Aktien am selben Tag, dem 10.10.2025, durch Ausübung von Aktienoptionen seitens des Emittenten erworben und in bar bezahlt wurden. Es gab 27.831.698 ausstehende Aktien, die für die Klasse vermerkt sind. In den letzten drei Monaten wurden keine Wertpapiere verkauft. Der Einreicher bestätigt, dass er sich keiner nicht offengelegten materialadversen Informationen bewusst ist, und der Hinweis enthält die standardmäßige Bestätigung über Handelspläne und strafrechtliche Folgen bei falschen Aussagen.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed by FENC report?

It reports a proposed sale of 1,775 common shares with an aggregate market value of $16,401.00, to be sold approximately on 10/10/2025 on NASDAQ.

How were the shares being sold acquired according to the filing?

The shares were acquired on 10/10/2025 by a stock option exercise from the issuer and paid for in cash.

Who is the broker named for the planned sale in the FENC Form 144?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza.

Does the filing indicate recent sales by the same person?

No. The filing states "Nothing to Report" for securities sold during the past three months.

How many shares outstanding does the filing show for the class?

The filing lists 27,831,698 shares outstanding for the class.
Fennec Pharmaceuticals Inc

NASDAQ:FENC

FENC Rankings

FENC Latest News

FENC Latest SEC Filings

FENC Stock Data

259.67M
22.89M
16.25%
57.88%
4.48%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
RESEARCH TRIANGLE PARK